Jefferies Reiterates Buy Rating on Kezer Life Sciences (KZR) Ahead of '616 PhII Lupus Nephritis Data
Tweet Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Buy rating and $15.00 price target on Kezer Life Sciences (NASDAQ: KZR) noting the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
